CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
The Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET
Location: New York, NY
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
H.C. Wainwright 2nd Annual BioConnect Investor Conference
Fireside Chat: Monday, May 20, 2024 at 10:30 am ET
Location: New York, NY
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.21 |
| Daily Change: | -0.14 -5.96 |
| Daily Volume: | 3,654,074 |
| Market Cap: | US$276.160M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
